Jazz Pharmaceuticals Engages in Significant Investor Events for 2026

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is set to make notable appearances at important investor events in early 2026. The company will host a pivotal investor webcast on January 9, 2026, to present findings from the Phase 3 zanidatamab HERIZON-GEA-01 trial. This presentation is scheduled to occur at 6:30 AM PT / 3:30 PM GMT, and will feature commentary from senior management, including insights from Dr. Geoffrey Ku, an Associate Attending physician at the Memorial Sloan Kettering Cancer Center, specializing in Gastrointestinal Oncology. This webcast follows the oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), taking place the day prior, on January 8, 2026.

In addition, Jazz Pharmaceuticals will partake in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. During this event, Renee Gala, the company's president and CEO, will offer an overview of the company's strategy along with a recent business update. Her presentation is scheduled for 11:15 AM PST / 7:15 PM GMT. Investors interested in these discussions can access audio webcasts through the Investors section of the Jazz Pharmaceuticals website, with replays available for 30 days post-event.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a leading global biopharmaceutical company on a mission to innovate and transform the lives of patients suffering from serious diseases, often providing groundbreaking treatments where little or no options existed before. Headquartered in Dublin, Ireland, the company has a diverse portfolio that includes prominent therapies for sleep disorders and epilepsy, and is expanding its range of cancer treatments. Jazz Pharmaceuticals adopts a patient-first philosophy, focusing on science-driven research and development to create life-changing medicines.

With a commitment to patient care, Jazz has made significant advancements within its pipeline, particularly in the fields of oncology and neuroscience. The company's global reach includes research facilities, manufacturing plants, and dedicated employees working towards better health outcomes for people worldwide.

For more information regarding Jazz Pharmaceuticals and its initiatives, please visit www.jazzpharmaceuticals.com.

Conclusion

As these events draw closer, Jazz Pharmaceuticals continues to demonstrate its commitment to innovation and improvement in patient health. Stakeholders should mark their calendars for these essential presentations, which promise to highlight the company’s dynamic approach to overcoming medical challenges through groundbreaking treatments.